Tyler Brooks
The Momentum Trader
Mobix Labs Acquires Vision Aerial: A Strategic Move in National Security Tech
Mobix Labs secures Vision Aerial for $15M, enhancing its defense tech portfolio and positioning in d…
Canada's CPI Decline: Implications for the Bank of Canada and Investors
Canada's June CPI shows a year-over-year increase of 2.8%, raising questions about future Bank of Ca…
Surge in US Housing Starts: A Promising Indicator for the Economy
US housing starts jumped 19% in June, signaling a robust economic outlook and potential shifts in Fe…
Market Volatility: S&P 500 and Nasdaq Futures React to US-Iran Tensions
Geopolitical tensions impact S&P 500 and Nasdaq futures, sending chip stocks into a tailspin. Trader…
Gladstone Investment's Acquisition of DHE Computer Systems: Implications for Tech Investors
Gladstone Investment's acquisition of DHE Computer Systems signals strong interest in tech investmen…
Ondas Holdings Expands Portfolio with $875.8M Acquisition of DZYNE
Ondas Holdings is set to acquire DZYNE for $875.8M, marking a significant move in the defense sector…
US Oil Companies Report Profit Surge Amid Political Tensions with Trump Administration
US oil companies see profit increases as political tensions rise; investors should watch for impacts…
Larimar Therapeutics Faces Setback with Partial BLA Submission for Nomlabofusp
Larimar Therapeutics' stock slides after a partial BLA submission delays FDA review timelines for no…
Calian Group Expands Reach with Galaxy Broadband Acquisition
Calian Group is set to enhance its market presence with the acquisition of Galaxy Broadband for up t…
CRH's $8 Billion Acquisition of Arcosa: A Major Infrastructure Move
CRH's potential $8 billion acquisition of Arcosa could reshape the construction materials sector sig…
Prime Medicine's PM359 Lands FDA RMAT Designation: What It Means for Gene Therapy
Prime Medicine ($PRME) secures FDA RMAT status for PM359 in CGD treatment, signaling accelerated dev…
REGENXBIO's Path to FDA Approval: A Key Milestone for NAVSUNLI
REGENXBIO aligns with the FDA for NAVSUNLI resubmission, a crucial step for investors to monitor.
Spero Therapeutics Soars Following FDA Approval of Utebzi
Spero Therapeutics shares jumped 16% after FDA approval of Utebzi, signaling strong market confidenc…
Natural Gas Services Expands with $120 Million Acquisition of Flatrock Compression
Natural Gas Services is set to enhance its market position with the $120 million acquisition of Flat…
Everlert's Potential Acquisition of Rimrock: A Look into Copper-Gold Prospects
Everlert (OTC: EVLI) is in talks for the Rimrock Copper-Gold Project. What does this mean for trader…
Quantum Space SPAC Deal Signals Hot Money Flowing Into Space Tech
Quantum Space's public debut via Inflection Point SPAC merger highlights growing investor appetite f…
Gilead's Acquisition of Ouro Medicines: A Strategic Boost for Oncology
Gilead Sciences enhances its oncology capabilities with the acquisition of Ouro Medicines, positioni…
AbbVie's FDA Approval of DECNUPAZ: A New Era for Rare Blood Cancer Treatment
AbbVie secures FDA approval for DECNUPAZ, marking a pivotal moment in its oncology pipeline and stoc…
Aptose Biosciences Provides Update on Hanmi Pharmaceutical Deal Closing Timeline
Aptose updates the timeline for its deal with Hanmi, shedding light on regulatory implications and t…
Humacyte's VA Contract: A Milestone for Symvess Surgical Implants
Humacyte secures a vital contract with the VA for Symvess, boosting access to 170 hospitals and high…